Contact

Our portfolio

Kling Biotherapeutics

Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.

  • Institute: Amsterdam UMC
Industry: Infectious Disease, Oncology, Therapeutics
  • Founding year: 2021
Visit website

Want to get in contact about Kling Biotherapeutics?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
AtMoves
Improving orthopedic diagnostics with advanced joint loading device and AI-based imaging technology.

OpticsFoundry

OpticsFoundry
Revolutionizing optical circuit manufacturing by offering robotically assembled and modular optical circuit boards that are easy to design, order, and deploy.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Parkinnova Therapeutics
Developing novel treatments for Parkinson’s disease and dopamine disorders.
AtMoves
Improving orthopedic diagnostics with advanced joint loading device and AI-based imaging technology.

OpticsFoundry

OpticsFoundry
Revolutionizing optical circuit manufacturing by offering robotically assembled and modular optical circuit boards that are easy to design, order, and deploy.
Arthrogen
Developing local gene therapy for chronic diseases, Arthrogen utilizes viral-mediated gene transfer to treat conditions like rheumatoid arthritis.
Explore full AAV portfolio
Contact